Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).


Abulkhair O., Uslu R., Sezgin C., Bueyuekberber S., Darwish T., Isikdogan A., ...Daha Fazla

CANCER RESEARCH, cilt.72, 2012 (SCI İndekslerine Giren Dergi) identifier